Trial Profile
A Clinical Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745, to Evaluate the Effects of 12-Week Oral Twice-Daily Dosing on Amyloid Plaque Load as Assessed by Quantitative Dynamic 11C-PiB Positive Emission Tomography (PET) Amyloid Scanning
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Apr 2023
Price :
$35
*
At a glance
- Drugs Neflamapimod (Primary)
- Indications Alzheimer's disease
- Focus Biomarker; Therapeutic Use
- Sponsors EIP Pharma
- 03 Apr 2023 According to an EPI Pharmaceuticals media release, company today announced oral presentation by academic investigators from Amsterdam University Medical Center of neuroimaging results from this clinical study in patients with early Alzheimer's disease (AD) at International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) 2023, which took place virtually and in person Mar 28-Apr 1, 2023, in Gothenburg, Sweden.
- 02 Dec 2022 Results presented in an EPI Pharmaceuticals Media Release.
- 02 Dec 2022 According to an EPI Pharmaceuticals media release, data presented at the 15th Annual Clinical Trials in Alzheimer's disease (CTAD) meeting.